Is Curcumin at the Threshold of Therapeutic Effectiveness on Patients with Colon Cancer?—A Systematic Review

Curcumin, obtained from curcuma longa, has been the subject of decades of scientific investigation on its therapeutic usefulness. It is reported to possess several therapeutic properties, of which anti-colon cancer is of interest in this review. Clinically however, curcumin has yet to firm up its place among established anti-colon cancer therapeutic contenders. We aimed to systematically review prevailing clinical evidence on the role of curcumin in colon cancer treatment. The review drawing from literature on clinical studies indicates fairly long term tolerability. No regression of tumor was reported when curcumin was the sole intervention. Increase in p53 level expression was reported in a placebo controlled study but no reduction in PGE2 or 5HETE. Pharmacokinetic data on healthy humans indicate that formulated curcumin delivery systems present significantly higher systemic bioavailability. It appears therefore that the clinical use of curcumin can potentially be realized only through appropriate formulation interventions.Systematic Review Registration: [website], identifier [registration number]

Download Full-text

Is curcumin at the threshold of therapeutic effectiveness on patients with colon cancer? – A systematic review

10.29117/quarfe.2021.0118 ◽

2021 ◽

Author(s):

Laila Khaled Shafei ◽

Mohamed Izham ◽

Nashiru Billa

Keyword(s):

Colon Cancer ◽

Curcuma Longa ◽

Controlled Study ◽

Pharmacokinetic Data ◽

Healthy Humans ◽

Systemic Bioavailability ◽

Term Tolerability ◽

The Subject

Curcumin, obtained from Curcuma longa, has been the subject of decades of scientific investigation on its therapeutic usefulness. It is reported to possess several therapeutic properties, of which anti-colon cancer is of interest in this review. Clinically, however, curcumin has yet to firm up its place among established anti-colon cancer therapeutic contenders. We aimed to systematically review the prevailing clinical evidence on the role of curcumin in colon cancer treatment. The review drawing from literature on clinical studies indicates fairly long-term tolerability. No regression of tumor was reported when curcumin was the sole intervention. An increase in p53 level expression was reported in a placebo-controlled study but no reduction in PGE2 or 5HETE. Pharmacokinetic data on healthy humans indicate that formulated curcumin delivery systems present significantly higher systemic bioavailability. It appears therefore that the clinical use of curcumin can potentially be realized only through appropriate formulation interventions

Download Full-text

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2017-019368 ◽

2019 ◽

Vol 9 (3) ◽

pp. e019368 ◽

Cited By ~ 3

Author(s):

Bruno Rodrigues Rosa ◽

Antonio José Ledo Alves da Cunha ◽

Roberto de Andrade Medronho

Keyword(s):

Systematic Review ◽

Incomplete Data ◽

Meta Analysis ◽

Randomised Trials ◽

Dengue Vaccine ◽

Eligibility Criteria ◽

Registration Number ◽

Randomised Controlled

BackgroundRandomised controlled trials have evaluated the recombinant tetravalent dengue vaccine (CYD-TDV). However, individual results may have little power to identify differences among the populations studied.ObjectiveTo evaluate efficacy, immunogenicity and safety of CYD-TDV in the prevention of dengue in children aged 2–17 years.DesignSystematic review and meta-analysis.Data sourcesMEDLINE (from 1950 to 5 December 2018), EMBASE (from 1947 to 5 December 2018) and Cochrane (from 1993 to 5 December 2018).Eligibility criteria of studiesRandomised trials comparing efficacy, immunogenicity and safety of CYD-TDV with placebo or other vaccines for preventing dengue cases in children aged 2–17 years.Outcome measuresEfficacy, immunogenicity and safety of CYD-TDV.Study appraisal and methodsCalculations were made of relative risk (RR) and mean difference (MD) for dichotomous and continuous outcomes, respectively. All estimates were calculated considering a 95% CI estimate. A p<0.05 was considered statistically significant.ResultsNine studies involving 34 248 participants were included. The overall efficacy of CYD-TDV was 60% (RR 0.40 (0.30 to 0.54)). Serotype-specific efficacy of the vaccine was 51% for dengue virus type-1 (DENV-1) (RR 0.49 (0.39 to 0.63)); 34% for DENV-2 (RR 0.66 (0.50 to 0.86)); 75% for DENV-3 (RR 0.25 (0.18 to 0.35)) and 77% for DENV-4 (RR 0.23 (0.15 to 0.34)). Overall immunogenicity (MD) of CYD-TDV was 225.13 (190.34 to 259.93). Serotype-specific immunogenicity was: DENV-1: 176.59 (123.36 to 229.83); DENV-2: 294.21 (181.98 to 406.45); DENV-3: 258.78 (146.72 to 370.84) and DENV-4: 189.35 (141.11 to 237.59). The most common adverse events were headache and pain at the injection site.LimitationsThe main limitation of this study was unclear or incomplete data.Conclusions and implications of key findingsCYD-TDV is considered safe and able to partially protect children and adolescents against four serotypes of DENV for a 1-year period. Despite this, research should prioritise improvements in vaccine efficacy, thus proving higher long-term protection against all virus serotypes.PROSPERO registration numberCRD42016043628.

Download Full-text

Laparoscopic vs open approach for transverse colon cancer. A systematic review and meta-analysis of short and long term outcomes

International Journal of Surgery ◽

10.1016/j.ijsu.2017.03.050 ◽

2017 ◽

Vol 41 ◽

pp. 78-85 ◽

Cited By ~ 25

Author(s):

Christos D. Athanasiou ◽

Jonathan Robinson ◽

Marina Yiasemidou ◽

Sonia Lockwood ◽

Georgios A. Markides

Keyword(s):

Systematic Review ◽

Colon Cancer ◽

Transverse Colon ◽

Meta Analysis ◽

Open Approach ◽

Transverse Colon Cancer ◽

Long Term Outcomes ◽

Short And Long Term

Download Full-text

Vitamin K status, supplementation and vascular disease: a systematic review and meta-analysis

Heart ◽

10.1136/heartjnl-2018-313955 ◽

2018 ◽

pp. heartjnl-2018-313955 ◽

Cited By ~ 12

Author(s):

Jennifer Susan Lees ◽

Fiona A Chapman ◽

Miles D Witham ◽

Alan G Jardine ◽

Patrick B Mark

Keyword(s):

Systematic Review ◽

Clinical Trials ◽

Longitudinal Studies ◽

Vitamin K ◽

Cardiovascular Health ◽

Meta Analysis ◽

Matrix Gla Protein ◽

Registration Number ◽

Meta Analyses

ObjectivesVascular stiffness (VS) and vascular calcification (VC) are surrogate markers of vascular health associated with cardiovascular events. Vitamin K-dependent proteins (VKDP) are associated with VS and VC and require vitamin K for activity. We conducted a systematic review and meta-analysis of: (1) the effect of vitamin K supplementation on VS and VC and (2) association of inactive VKDP levels with incident cardiovascular disease and mortality.MethodsTwo authors searched MEDLINE and Embase databases and Cochrane and ISRCTN registries for studies of vitamin K clinical trials that measured effects on VC, VS or VKDP and longitudinal studies assessing effect of VKDP on incident CVD or mortality. Random effects meta-analyses were performed.ResultsThirteen controlled clinical trials (n=2162) and 14 longitudinal studies (n=10 726) met prespecified inclusion criteria. Vitamin K supplementation was associated with significant reduction in VC (−9.1% (95% CI −17.7 to −0.5); p=0.04) and VKDP (desphospho-uncarboxylated matrix Gla protein; −44.7% (95% CI −65.1 to −24.3), p<0.0001) and uncarboxylated osteocalcin; −12.0% (95% CI −16.7 to −7.2), p<0.0001) compared with control, with a non-significant improvement in VS. In longitudinal studies with median follow-up of 7.8 (IQR 4.9–11.3) years, VKDP levels were associated with a combined endpoint of CVD or mortality (HR 0.45 (95% CI 0.07 to 0.83), p=0.02).ConclusionsSupplementation with vitamin K significantly reduced VC, but not VS, compared with control. The conclusions drawn are limited by small numbers of studies with substantial heterogeneity. VKDP was associated with combined endpoint of CVD or mortality. Larger clinical trials of effect of vitamin K supplementation to improve VC, VS and long-term cardiovascular health are warranted.Trial registration numberCRD42017060344.

Download Full-text

The long-term tolerability of bencyclane (‘Fludilat’) in patients with peripheral occlusive disease: A 48-week prospective double-blind controlled study versus placebo

Current Medical Research and Opinion ◽

10.1185/03007999109111505 ◽

1991 ◽

Vol 12 (6) ◽

pp. 356-365

Author(s):

W. M. Herrmann ◽

E. Schärer

Keyword(s):

Occlusive Disease ◽

Controlled Study ◽

Double Blind ◽

Term Tolerability ◽

Peripheral Occlusive Disease

Download Full-text

Short- and long-term outcomes after transverse versus extended colectomy for transverse colon cancer. A systematic review and meta-analysis

International Journal of Colorectal Disease ◽

10.1007/s00384-018-3186-4 ◽

2018 ◽

Vol 34 (2) ◽

pp. 201-207 ◽

Cited By ~ 4

Author(s):

Marco Milone ◽

Michele Manigrasso ◽

Ugo Elmore ◽

Francesco Maione ◽

Nicola Gennarelli ◽

...

Keyword(s):

Systematic Review ◽

Colon Cancer ◽

Transverse Colon ◽

Meta Analysis ◽

Transverse Colon Cancer ◽

Long Term Outcomes ◽

Short And Long Term

Download Full-text

Interventions by healthcare professionals to improve management of physical long-term conditions in adults who are homeless: a systematic review protocol

BMJ Open ◽

10.1136/bmjopen-2017-016756 ◽

2017 ◽

Vol 7 (8) ◽

pp. e016756 ◽

Cited By ~ 5

Author(s):

Peter Hanlon ◽

Lynsey Yeoman ◽

Regina Esiovwa ◽

Lauren Gibson ◽

Andrea E Williamson ◽

...

Keyword(s):

Systematic Review ◽

Healthcare Professional ◽

Randomised Controlled Trials ◽

Healthcare Professionals ◽

Controlled Trials ◽

Long Term Conditions ◽

Homeless Adults ◽

Registration Number ◽

Randomised Controlled

IntroductionPeople experiencing homelessness are at increased risk of, and have poorer outcomes from, a range of physical long-term conditions (LTCs). It is increasingly recognised that interventions targeting people who are homeless should be tailored to the specific needs of this population. This systematic review aims to identify, describe and appraise trials of interventions that aim to manage physical LTCs in homeless adults and are delivered by healthcare professionals.Methods and analysisSeven electronic databases (Medline, EMBASE, Cochrane Central Register of Controlled Trials, Assia, Scopus, PsycINFO and CINAHL) will be searched from 1960 (or inception) to October 2016 and supplemented by forward citation searching, handsearching of reference lists and searching grey literature. Two reviewers will independently review titles, abstract and full-texts using DistillerSR software. Inclusion criteria include (1) homeless adults with any physical LTC, (2) interventions delivered by a healthcare professional (any professional trained to provide any form of healthcare, but excluding social workers and professionals without health-related training), (3) comparison with usual care or an alternative intervention, (4) report outcomes such as healthcare usage, physical and psychological health or well-being or cost-effectiveness, (5) randomised controlled trials, non-randomised controlled trials, controlled before-after studies. Quality will be assessed using the Cochrane EPOC Risk of Bias Tool. A meta-analysis will be performed if sufficient data are identified; however, we anticipate a narrative synthesis will be performed.Ethics and disseminationThis review will synthesise existing evidence for interventions delivered by healthcare professionals to manage physical LTCs in adults who are homeless. The findings will inform the development of future interventions and research aiming to improve the management of LTCs for people experiencing homelessness. Ethical approval will not be required for this systematic review as it does not contain individual patient data. We will disseminate the results of this systematic review via conference presentations, healthcare professional networks, social media and peer-reviewed publication.Trial registration numberPROSPERO registration number: CRD42016046183.

Download Full-text

Effects of Message Framing and Time Discounting on Health Communication for Optimum Cardiovascular Disease and Stroke Prevention (EMT-OCSP): a protocol for a pragmatic, multicentre, observer-blinded, 12-month randomised controlled study

BMJ Open ◽

10.1136/bmjopen-2020-043450 ◽

2021 ◽

Vol 11 (3) ◽

pp. e043450

Author(s):

Muke Zhou ◽

Jian Guo ◽

Ning Chen ◽

Mengmeng Ma ◽

Shuju Dong ◽

...

Keyword(s):

Cardiovascular Disease ◽

Risk Factor ◽

Message Framing ◽

Potential Interaction ◽

Controlled Study ◽

Cvd Risk ◽

Randomised Controlled Study ◽

Registration Number ◽

Randomised Controlled

IntroductionPrimary prevention of cardiovascular disease (CVD) and stroke often fails due to poor adherence among patients to evidence-based prevention recommendations. The proper formatting of messages portraying CVD and stroke risks and interventional benefits may promote individuals’ perception and motivation, adherence to healthy plans and eventual success in achieving risk control. The main objective of this study is to determine whether risk and intervention communication strategies (gain-framed vs loss-framed and long-term vs short-term contexts) and potential interaction thereof have different effects on the optimisation of adherence to clinical preventive management for the endpoint of CVD risk reduction among subjects with at least one CVD risk factor.Methods and analysisThis trial is designed as a 2×2 factorial, observer-blinded multicentre randomised controlled study with four parallel groups. Trial participants are aged 45–80 years and have at least one CVD risk factor. Based on sample size calculations for primary outcome, we plan to enrol 15 000 participants. Data collection will occur at baseline, 6 months and 1 year after randomisation. The primary outcomes are changes in the estimated 10-year CVD risk, estimated lifetime CVD risk and estimated CVD-free life expectancy from baseline to the 1-year follow-up.Ethics and disseminationThis study received approval from the Ethical Committee of West China Hospital, Sichuan University and will be disseminated via peer-reviewed publications and conference presentations.Trial registration numberNCT04450888.

Download Full-text